AI Innovators with Global Expertise

Since launching as a spin-out from the University of Oxford, Brainomix has pioneered the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions.

Our Brainomix 360 Stroke platform is the world's most comprehensive stroke imaging solution, widely adopted across multiple healthcare systems worldwide.

Building on this legacy and success, we are expanding beyond stroke into new areas, where there are similar unmet needs and opportunities to improve diagnosis and treatment.

Born in Oxford

As a spinout from the University of Oxford, Brainomix has a strong academic heritage and ongoing commitment to scientific excellence, with a world-class team driving continual innovation representing the frontiers of AI imaging advancements.

"In terms of the future, we are seeing that AI is transforming healthcare and we are part of this wave. With what we are doing now, we are seeing impact on a daily basis," Dr Michalis Papadakis, CEO and Co-Founder of Brainomix.

Value-Generating Partnerships

Over the years, Brainomix has formed a number of key partnerships that have enabled us to broaden our reach, expand our portfolio, and deliver innovative, end-to-end solutions to customers.

Learn more about our focus on creating value-generating partnerships that can improve clinical trial success and foster broad adoption of existing therapies in stroke, lung fibrosis and cancer.

Expanding Access to Life-Saving Treatments

At Brainomix, we are committed to developing innovative AI solutions that will improve patient outcomes.

Take a moment to learn about Margaret's story, a patient from Milton Keynes who suffered a stroke, but who was quickly diagnosed, transferred and treated - all with the help of Brainomix's technology.